Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Total Current Liabilities: 2020-2025

Historic Total Current Liabilities for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $28.1 million.

  • Caribou Biosciences' Total Current Liabilities fell 12.75% to $28.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.1 million, marking a year-over-year decrease of 12.75%. This contributed to the annual value of $30.7 million for FY2024, which is 8.30% up from last year.
  • Per Caribou Biosciences' latest filing, its Total Current Liabilities stood at $28.1 million for Q3 2025, which was down 2.87% from $28.9 million recorded in Q2 2025.
  • Caribou Biosciences' Total Current Liabilities' 5-year high stood at $34.4 million during Q2 2023, with a 5-year trough of $24.6 million in Q3 2023.
  • Its 3-year average for Total Current Liabilities is $29.3 million, with a median of $28.9 million in 2025.
  • Per our database at Business Quant, Caribou Biosciences' Total Current Liabilities soared by 108.48% in 2021 and then fell by 14.72% in 2023.
  • Caribou Biosciences' Total Current Liabilities (Quarterly) stood at $25.8 million in 2021, then increased by 8.90% to $28.1 million in 2022, then climbed by 0.62% to $28.3 million in 2023, then increased by 8.30% to $30.7 million in 2024, then dropped by 12.75% to $28.1 million in 2025.
  • Its Total Current Liabilities was $28.1 million in Q3 2025, compared to $28.9 million in Q2 2025 and $28.5 million in Q1 2025.